Opinion and Evidence for Treatments in Endocrine Disorders

Ma P, Wang Y, van der Hoek J, et al. Pharmacokinetic-pharmacodynamic comparison of a novel multiligand soniatostatin analog, SOM230, with octreotide in patients with acromegaly. Clin Pharmacol Ther 2005 Jul; 78(1): 69–80 Van Honk J, Peper JS, Schutter DJ. Testosterone reduces unconscious fear but not consciously experienced anxiety: implications for the disorders of fear and anxiety. Biol Psychiatry 2005 Aug 1; 58(3): 218–25 Roden M, Laakso M, Johns D, et al. Long-term effects of pioglitazone and metformin on insulin sensitivity in patients with type 2 diabetes mellitus. Diabet Med 2005 Aug; 22(8): 1101–6 Pandya KJ, Morrow GR, Roscoe JA, et al. Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. Lancet 2005 Sep 3–9; 366(9488): 818–24 Zhang Q, Menditto L. Incremental cost savings 6 months following initiation of insulin glargine in a Medicaid fee-for-service sample. Am J Ther 2005 Jul–Aug; 12(4): 337–43 Popat RA, Van Den Eeden SK, Tanner CM, et al. Effect of reproductive factors and postmenopausal hormone use on the risk of Parkinson disease. Neurology 2005 Aug 9; 65(3): 383–90 Feinglos MN, Saad MF, Pi-Sunyert FX, et al. Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with type 2 diabetes. Diabet Med 2005 Aug; 22(8): 1016–23 Aloia JF, Talwar SA, Pollack S, et al. A randomized controlled trial of vitamin D3 supplementation in African American women. Arch Intern Med 2005 Jul 25; 165(14): 1618–23 Freda PU, Katznelson L, van der Lely AJ, et al. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab 2005 Aug; 90(8): 4465–73 Yki-Järvinen H. The PROactive study: some answers, many questions. Lancet 2005 Oct 8; 366(9493): 1241–2 Freemantle N. How well does the evidence on pioglitazone back up researchers’ claims for a reduction in macrovascular events? BMJ 2005 Oct; 331(7520): 836–8 Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macro Vascular Events): a randomised controlled trial. Lancet 2005 Oct 8; 366(9493): 1279–89 Reid IR, Miller P, Lyles K, et al. Comparison of a single infusion of zoledronic acid with risedronate for Paget’s disease. N Engl J Med 2005 Sep 1; 353(9): 898–908 Tonstad S, Tykarski A, Weissgarten J, et al. Efficacy and safety of topiramate in the treatment of obese subjects with essential hypertension. Am J Cardiol 2005 Jul 15; 96(2): 243–51 Recker RR, Gallagher R, MacCosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 2005 Jul; 80(7): 856–61 American Diabetes Association European Association for the Study of Diabetes (EASD). Metabolic syndrome: a misleading ‘diagnosis’: media release 25 Aug 2005 [online]. Available from URL: http://www.diabetes.org Yasuda G, Ando D, Hirawa N, et al. Effects of losartan and amlodipine on urinary albumin excretion and ambulatory blood pressure in hypertensive type 2 diabetic patients with overt nephropathy. Diabetes Care 2005 Aug 8; 28: 1862–8 Cundy T, Davidson J, Rutland MD, et al. Recombinant osteoprotegerin for juvenile Paget’s disease. N Engl J Med 2005 Sep 1; 353(9): 918–23 Grobbee DE. LIFT study to continue as planned. BMJ 2005 Oct 8; 331(7520): 843 International Diabetes Federation. Global guidelines for type 2 diabetes, 2005 [online]. Available from URL: http://www.idf.org International Diabetes Federation. International Diabetes Federation launches first global guideline for management of type 2 diabetes: media release 13 Sep 2005 [online]. Available from URL: http://www.idf.org The Global Partnership for Effective Diabetes Management. International diabetes experts launch first global recommendations for effective management of type 2 diabetes: media release 12 Oct 2005 [online]. Available from URL: http://www.idf.org